Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
US12233104B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 7, 2016 |
| Grant date | Feb 25, 2025 |
| Priority date | — |
| Expiry date | Apr 12, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In one or more embodiments of the invention, a method is provided, the method comprising the steps of administering to a cancer patient: (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a composition is provided, the composition comprising: an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a kit is provided, the kit comprising: an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; an IL-15R-activating amount of a long-acting, IL-15 moiety; and instructions for use of the IL-2Rβ-selective agonist and the long-acting, IL-15 moiety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.